De Felice Francesca, Musio Daniela, Tombolini Vincenzo
Department of Radiotherapy, Policlinico Umberto I, "Sapienza" University of Rome, 00161 Rome, Italy.
J Pers Med. 2021 May 10;11(5):393. doi: 10.3390/jpm11050393.
In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.
在头颈癌治疗中，需要采用量身定制的方法来优化临床疗效。基于标准的铂类同步放化疗在疗效和长期毒性方面不尽人意这一假设，已设计了多项试验来检验诱导免疫治疗和/或同步免疫治疗及放疗是否能改善生存和毒性结果。在此，我们概述了头颈癌最新的同步治疗策略，重点关注有关检查点抑制剂的现有知识。目的是介绍主要检查点抑制剂的特点，并总结在确定性头颈癌治疗中免疫检查点抑制剂与（放）化疗联合应用的临床试验，以便为进一步研究提供有用的临床工具。
